BioNTech SE business relationships
Companies named in BioNTech SE’s 20-F filed 2026-03-10, and public companies whose annual reports name BioNTech SE. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in BioNTech SE’s annual report 13
“(3) Partnered with Bristol Myers Squibb.” SEC filing
“collaboration partner Pfizer, higher expenses from inventory scrapping and write-downs to net realizable value” SEC filing
“(10) In collaboration with Regeneron.” SEC filing
“We and our partner Roche have decided to discontinue the Phase 2 clinical trial (IMcode004; NCT06534983)” SEC filing
“subsidiary, BioNTech RNA Pharmaceuticals GmbH, or BioNTech RNA, and Siemens announced a collaboration” SEC filing
“Because the information supplied by Pfizer is” SEC filing
“Side Letter No. 5 to License and Collaboration Agreement by and between Registrant and Genmab A/S, dated August 12,” SEC filing
“License Agreement by and between the Registrant and Acuitas Therapeutics, Inc., dated as of April 7, 2020 (incorporated” SEC filing
“For example, we and our collaborators rely on WuXi Biologics Co., Ltd. and its affiliates for outsourcing” SEC filing
“exclusively licensed to Genentech, and their interest in any jointly-owned intellectual property developed under” SEC filing
“being developed with our collaborator, Genentech.” SEC filing
“Supply Agreement with Genentech and F.” SEC filing
“License and Collaboration Agreement, by and between the Registrant and OncoC4, Inc., dated as of March 17, 2023” SEC filing
Companies whose annual reports name BioNTech SE 10
“During 2025, we entered into a global strategic collaboration with BioNTech for the co-development and co-commercialization of pumitamig (BNT327/BMS986545), a potentially transformative PD-L1/VEGF-A bispecific that could set a new standard of care across multiple tumor types.” SEC filing
“In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19 vaccines to the EU.” SEC filing
“(18) Product is being commercialized in collaboration with BioNTech.” SEC filing
“We filed a resale registration statement on Form S-3 to register the ADSs we sold to BioNTech in 2024.” SEC filing
“The royalty will be increased if BioNTech, its affiliates or sublicensees commercialize a Binder Licensed Product in an indication and country in which we or our affiliates or licensees also commercialize a product containing the same binders.” SEC filing
“Under the License Agreement, BioNTech has also agreed to financially support the expansion of the clinical development program and planned commercialization of obe-cel.” SEC filing
“• our plans to collaborate, or statements regarding our current collaborations with BioNTech SE ("BioNTech") and others;” SEC filing
“Other companies with selective KRAS inhibitors include AstraZeneca (in collaboration with Usynova), BioNTech, Roche, Merck/Moderna, Boehringer and Gilead.” SEC filing
“...id tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics Inc.), pumitamig (co-developed by BioNTech SE and Bristol Myers Squibb), LM-299 (LaNova Medicines Ltd.; in-licensed by Merck), SSGJ-707 (3SBio Inc.; in-licensed by Pfizer), and CTX-10726 (Compass Therapeutics, Inc....” SEC filing
“These include, but are not limited to pumitamig (BNT327), which is owned by BioNTech SE and being developed in a collaboration with Bristol Myers Squibb Co. since June 2025, which has begun conducting Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally,...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.